Alexis B. Cortot

11.3k citations

185 papers · 3.8k indexed · 2 hit papers · h-index 28

Pulmonary and Respiratory Medicine top 0.5%
Oncology top 1%
Molecular Biology top 5%
Cancer Research top 5%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Pasi A. Jänne Dalia Ercan Marzia Capelletti Nathanael S. Gray Kwok‐Kin Wong Marie Wislez Julien Mazières Cai‐Hong Yun
Topics: Lung Cancer Treatments and Mutations (121 papers)Lung Cancer Research Studies (44 papers)Lung Cancer Diagnosis and Treatment (43 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Journals: Nature Journal of Clinical Oncology JNCI Journal of the National Cancer Institute
Partner nations: France United States Germany

In The Last Decade

Alexis B. Cortot

167 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

2009 785 citations Dalia Ercan, Marzia Capelletti et al. profile →
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

2013 489 citations Julien Mazières, Solange Peters et al. profile →

Peers

Countries citing papers authored by Alexis B. Cortot

Since Specialization

Citations

This map shows the geographic impact of Alexis B. Cortot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexis B. Cortot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexis B. Cortot more than expected).

Fields of papers citing papers by Alexis B. Cortot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexis B. Cortot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexis B. Cortot. The network helps show where Alexis B. Cortot may publish in the future.

Co-authorship network of co-authors of Alexis B. Cortot

This figure shows the co-authorship network connecting the top 25 collaborators of Alexis B. Cortot. A scholar is included among the top collaborators of Alexis B. Cortot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexis B. Cortot. Alexis B. Cortot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study 2025 ·Lung Cancer ·(unknown),Laurent Greillier,Florian Guisier,Catherine Daniel,R. Descourt,Loïck Galland,Olivier Molinier,C. Decroisette,Alexis B. Cortot,(unknown),Laurence Gamé,Marie Wislez,Nicolas Cloarec,(unknown),(unknown),J. Cadranel,Boris Duchemann,(unknown),C. Chouaïd,J.B. Auliac	0
2	Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer 2025 ·Therapeutic Advances in Medical Oncology ·(unknown),(unknown),(unknown),(unknown),(unknown),Arnaud Scherpereel,Alexis B. Cortot,Clément Gauvain	1
3	Association épidémiologique entre pollution et altérations oncogéniques dans le cancer du poumon 2024 ·Revue des Maladies Respiratoires Actualités ·Serge Leblanc,Michaël Génin,Florent Occelli,(unknown),(unknown),S. Hominal,Acya Bizieux‐Thaminy,(unknown),(unknown),(unknown),L. Belmont,(unknown),David Renault,(unknown),(unknown),(unknown),Aghilès Hamroun,D. Debieuvre,Alexis B. Cortot	0
4	1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients 2023 ·Annals of Oncology ·Marc G. Denis,(unknown),Christine Sagan,(unknown),Audrey Vallée,Jacques Cadranel,Clarisse Audigier-Valette,Pascale Tomasini,Philippe Masson,(unknown),(unknown),Nicolas Girard,Alexis B. Cortot,(unknown),I. Monnet,M. Marcq,T. Urban,(unknown),H. Léna,Jaafar Bennouna	1
5	585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib 2023 ·Annals of Oncology ·Tony Mok,Geoffrey Liu,(unknown),(unknown),Alexis B. Cortot,(unknown),R. Descourt,(unknown),Parneet Cheema,(unknown),Eric N. Churchill,(unknown),(unknown),(unknown),Kelly K. Chong,(unknown),(unknown),Jacques Cadranel	1
6	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study 2022 ·Cancers ·R. Descourt,M. Pérol,(unknown),David Planchard,B. Mennecier,Marie Wislez,Jacques Cadranel,Alexis B. Cortot,Florian Guisier,Loïck Galland,Pascal Dô,Roland Schött,Éric Dansin,Jennifer Arrondeau,J.B. Auliac,Margaux Geier,C. Chouaïd	5
7	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study 2022 ·Cancers ·Jean‐Baptiste Assié,(unknown),Emmanuel Grolleau,Anthony Canellas,Margaux Geier,(unknown),(unknown),Aldo Renault,Pierre-Alexandre Hauss,(unknown),(unknown),Alexis B. Cortot,Marie Wislez,Clément Gauvain,C. Chouaïd,Arnaud Scherpereel,I. Monnet	11
8	Dual-Energy CT Perfusion of Invasive Tumor Front in Non–Small Cell Lung Cancers 2021 ·Radiology ·(unknown),Marie‐Christine Copin,Alain Duhamel,J Faivre,Valérie Deken,Martin Sedlmair,Thomas Flohr,Bernhard Schmidt,Alexis B. Cortot,(unknown),Jacques Rémy,Martine Rémy‐Jardin	16
9	Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database 2020 ·OncoImmunology ·(unknown),Johana Béné,Sophie Gautier,Aurélie Grandvuillemin,Christine Le Beller,Chouki Chenaf,Nicolas Etienne,(unknown),Alexis B. Cortot,Laurent Mortier,D. Staumont‐Sallé,Franck Morschhauser,Alexandra Forestier,Matthieu Groh,David Launay,É. Hachulla,Myriam Labalette,Jean‐Emmanuel Kahn,Guillaume Lefèvre	37
10	Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma 2020 ·Lung Cancer ·Simon Baldacci,V. Grégoire,Enrico Patrucco,Roberto Chiarle,Philippe Jamme,(unknown),(unknown),Marie‐Christine Copin,Mark M. Awad,Alexis B. Cortot	11
11	Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial 2019 ·Clinical Lung Cancer ·Jaafar Bennouna,Nicolas Girard,Clarisse Audigier-Valette,Aurélie Le Thuaut,Radj Gervais,Philippe Masson,M. Marcq,Olivier Molinier,Alexis B. Cortot,D. Debieuvre,J. Cadranel,H. Léna,Denis Moro‐Sibilot,C. Chouaïd,B. Mennecier,T. Urban,Christine Sagan,(unknown),Fabrice Barlési,Marc G. Denis	19
12	Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC 2018 ·Cancer Medicine ·Paul Lesueur,Alexandre Escande,Juliette Thariat,(unknown),I. Monnet,Alexis B. Cortot,D. Lerouge,S. Danhier,Pascal Dô,Catherine Dubos‐Arvis,C. Chouaïd,Radj Gervais	36
13	Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer 2017 ·European Radiology ·Grégory Kuchcinski,Émilie Le Rhun,Alexis B. Cortot,Élodie Drumez,(unknown),(unknown),(unknown),Renaud Lopes,Jean‐Pierre Pruvo,X. Leclerc,Christine Delmaire	12
14	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort 2015 ·Annals of Oncology ·Julien Mazières,Fabrice Barlési,Thomas Filleron,Benjamin Besse,I. Monnet,Michèle Beau‐Faller,Solange Peters,Éric Dansin,Martin Früh,Miklos Pless,Rafael Rosell,Marie Wislez,P. Fournel,Virginie Westeel,Federico Cappuzzo,Alexis B. Cortot,Denis Moro‐Sibilot,Julie Milia,Oliver Gautschi	219
15	La maladie de Castleman : observations inhabituelles et revue de la littérature 2013 ·Revue de Pneumologie Clinique ·(unknown),(unknown),B. Bouchindhomme,Nunzia Tacelli,(unknown),X. Dhalluin,J.J. Lafitte,Arnaud Scherpereel,Martine Rémy-Jardin,Alexis B. Cortot	1
16	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway 2012 ·Cancer Research ·Alexis B. Cortot,Claire E. Repellin,Takeshi Shimamura,Marzia Capelletti,Kreshnik Zejnullahu,Dalia Ercan,James G. Christensen,Kwok‐Kin Wong,Nathanael S. Gray,Pasi A. Jänne	163
17	Patterns of EGFR, HER2, TP53 , and KRAS Mutations of p14arf Expression in Non–Small Cell Lung Cancers in Relation to Smoking History 2007 ·Cancer Research ·Mounia Mounawar,Anush Mukeria,Florence Le Calvez‐Kelm,Rayjean J. Hung,Hélène Renard,Alexis B. Cortot,(unknown),Давид Заридзе,Paul Brennan,Paolo Boffetta,Élisabeth Brambilla,Pierre Hainaut	83
18	Lymphome pulmonaire du MALT révélant un sida 2006 ·Revue des Maladies Respiratoires ·Alexis B. Cortot,(unknown),B. Issartel,David Meyronet,Bertrand Coiffier,J.-F. Cordier	5
19	[An enigmatic occlusive syndrome]. 1988 ·PubMed ·(unknown),(unknown),(unknown),(unknown),Fabien Guillemot,Alexis B. Cortot,(unknown)	1
20	[Palliative treatment of cancer of the esophagus and cardia by laser photo-ablation]. 1987 ·PubMed ·(unknown),(unknown),(unknown),(unknown),Alexis B. Cortot,(unknown)	5

About Alexis B. Cortot

Alexis B. Cortot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology, having authored 185 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (121 papers), Lung Cancer Research Studies (44 papers) and Lung Cancer Diagnosis and Treatment (43 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.7k citations), Oncology (2.2k citations) and Cancer Research (609 citations). Alexis B. Cortot has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Pasi A. Jänne, Dalia Ercan, Marzia Capelletti, Nathanael S. Gray, Kwok‐Kin Wong, Marie Wislez, Julien Mazières, Cai‐Hong Yun, Michael J. Eck and John R. Engen. Their work appears in journals such as Nature, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact